SSDXP-13/CSID

I'm Interested!

Evaluation of a 7-Day Therapeutic Trial Dose of Commercial Sucraid® (sacrosidase) Oral Solution for Alleviating Congenital Sucrase-Isomaltase Deficiency (CSID) Symptoms in Pediatric Subjects with Low, Moderate, and Normal Sucrase Levels

Sex at Birth: Any
Age: Child (Birth - 17)
Accepting Healthy People: No
Type: Interventional / Therapeutic
Trial Phase: Phase IV
Conditions Being Studied: Sucrase

Study Purpose

The purpose of this study is to investigate the effects of Sucraid® (sacrosidase) Oral Solution 8500 IU/mL treatment on gastrointestinal symptoms in subjects with low, moderate, and normal disaccharidase assay sucrase levels from an esophagogastroduodenoscopy (EGD). This study aims to explore the relationship between known genetic CSID mutations and sucrase activities via (EGD) disaccharidase assay (low, moderate, and normal).

Who Can Participate

Age: 6 months - 17

Principal Investigator
Thomas Sferra MD

Department/Division
Gastroenterology (Pediatrics)

Locations

UH Cleveland Medical Center
11100 Euclid Avenue
Cleveland OH, 44106

Get Directions

UH IRB: SITE00001773
StudyID: 2022-0988
ClinicalTrials.gov: NCT05480761

I'm Interested!

Fill out our online form

Questions or concerns? We're here to help.

Non-cancer Trials: 1-833-78TRIAL or Contact Us Online

Cancer Trials: 1-800-641-2422